Ulipristal, a progesterone receptor antagonist as a contraceptive and for the treatment of uterine fibroids.

Curr Opin Investig Drugs. 2007 Oct;8(10):859-66

Authors: Orihuela PA

HRA Pharma, under license from the Research Triangle Institute, is developing ulipristal, a progesterone receptor modulator, for the potential use as a contraceptive and an emergency contraceptive, and for the potential treatment of uterine fibroids. Phase II clinical trials for uterine fibroids and phase III trials for contraception are underway. The drug was expected to be launched in the US and Europe in 2009.

PMID: 17907063 [PubMed - indexed for MEDLINE]

---

Comments (0)

Show/Hide comments

Write comment Show/Hide comment form

Name

Email

Title

Comment

Write the displayed characters

Add Comment